Try GOLD - Free

Digital Health Incentive Scheme (DHIS) analyzed

Healthcare Radius

|

September 2023

Industry experts share their views on the Digital Health Incentive Scheme (DHIS) in the backdrop of the recent extension given by NHA.

Digital Health Incentive Scheme (DHIS) analyzed

India's National Health Authority (NHA) announced an extension to the Digital Health Incentive Scheme (DHIS) under the Ayushman Bharat Digital Mission (ABDM) until December 31, 2023. The scheme encourages digital health adoption by hospitals, laboratories, pharmacies, and health-tech companies. Industry experts are hailing this move as a positive development with profound implications for various stakeholders in the healthcare sector.

Sachidanand Upadhyay, Founder, Lord's Mark Industries, applauds this decision and says, "Under DHIS, financial incentives are provided to hospitals, diagnostic labs, and health-tech companies for embracing digital transformation under ABDM. It is a remarkable step by NHA to announce the extension of DHIS till December 31, 2023. This extension broadens the program's relevance, allowing a wider range of stakeholders to reap the benefits of digital incentives." Upadhyay believes that this initiative has spurred the adoption of digital health technology across India. It will ensure swift access to healthcare services and secure health data through digital transactions.

Dr Vigyan Mishra, Chief of Lab, Neuberg Diagnostics, says, "Hospitals, labs, pharmacies, and health-tech companies have greatly benefited from this initiative. By incentivizing the adoption of digital health technologies, DHIS has paved the way for efficient data management, improved patient care, and enhanced operational efficiency." He points out that this extension has empowered hospitals to transition to electronic health records, enabled labs to manage test results efficiently, allowed pharmacies to optimize inventory and prescriptions, and encouraged health-tech companies to innovate. The results are less paperwork, faster information exchange, and better healthcare outcomes.

MORE STORIES FROM Healthcare Radius

Healthcare Radius

Healthcare Radius

VENUS REMEDIES GETS DRUG APPROVALS IN VIETNAM

Venus Remedies, a fixed-dosage injectable manufacturer, has secured new marketing authorisations for Methotrexate, Cefuroxime, and Irinotecan in Vietnam.

time to read

1 mins

December 2025

Healthcare Radius

Healthcare Radius

A HEALTHIER INDIA IN THE MAKING: LEADERS DECODE THE ROAD FROM 2025 TO 2026

The collective goal is clear and unanimous: to transition from a system that primarily treats sickness to one that actively promotes lifelong health and well-being.

time to read

12 mins

December 2025

Healthcare Radius

Healthcare Radius

FROM GENES TO CARE: ADVANCING CLINICAL UNDERSTANDING OF HYPOPHOSPHATASIA

From genes to care, the story of hypophosphatasia reminds us that progress in medicine isn't only about scientific discovery, it's about turning knowledge into healing.

time to read

6 mins

December 2025

Healthcare Radius

ALEMBIC PHARMA GETS USFDA NOD FOR DILTIAZEM TABLETS IN THE US

Alembic Pharmaceuticals (Alembic) Aamour announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg.

time to read

1 min

December 2025

Healthcare Radius

Healthcare Radius

ZYDUS GETS USFDA APPROVAL FOR PROSTATE CANCER INJECTABLE

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial (USRLD: Lupron Injection®, 1 mg/0.2 mL).

time to read

1 min

December 2025

Healthcare Radius

Healthcare Radius

SUPERHEALTH LAUNCHES HONEST SECOND OPINION FOR PATIENTS

Superhealth, a zero-wait, commission Superhealth, zerohospital network, announced the launch of \"Honest Second Opinion,\" a service that helps patients make informed decisions about their treatment plans and surgical recommendations.

time to read

1 min

December 2025

Healthcare Radius

Healthcare Radius

KOTAK ALTS INVESTS RS 400MN IN MEDIVERSAL

Kotak Alternate Asset Managers (Kotak Alts), through its Kotak Life Science Fund I, which invests in early to growth-stage life sciences and healthcare businesses, has made an investment of Rs 400 million in Mediversal Healthcare.

time to read

1 min

December 2025

Healthcare Radius

Healthcare Radius

INVIGA HEALTHCARE FUND ACQUIRES 21% STAKE IN FORUS HEALTH

Inviga Healthcare Fund (IHF), the private equity platform founded by Dr B. S. Ajaikumar of HCG, has acquired a 21 per cent stake in Forus Health, an ophthalmic diagnostics company whose devices have screened over 22 million patients across 75+ countries.

time to read

1 min

December 2025

Healthcare Radius

Healthcare Radius

OPTIMISING MATERNITY OPS: REDUCING C-SECTION BURDEN THROUGH EVIDENCE-BASED PROTOCOLS

By building systems that support safety, documentation, and respectful care, institutions can improve outcomes, lower litigation risks, and strengthen quality scores, achieving what healthcare should truly represent: Care Through Trust.”

time to read

7 mins

December 2025

Healthcare Radius

Healthcare Radius

MENTAL HEALTH CARE GOES DIGITAL WITH NEW THERAPY PLATFORM

Following the global observance and continuing the commitment to mental well-being, renowned clinical psychologist Kanika Jindal announced the launch of Harmony Therapy World, a holistic digital platform designed to bring emotional healing and psychological support to people everywhere, privately, compassionately, and without barriers.

time to read

1 min

December 2025

Translate

Share

-
+

Change font size